Mpox outbreak in the Netherlands, 2022: public health response, characteristics of the first 1,000 cases and protection of the first-generation smallpox vaccine
Catharina E van Ewijk,Fuminari Miura,Gini van Rijckevorsel,Henry Jc de Vries,Matthijs Ra Welkers,Oda E van den Berg,Ingrid Hm Friesema,Patrick R van den Berg,Thomas Dalhuisen,Jacco Wallinga,Diederik Brandwagt,Brigitte Agl van Cleef,Harry Vennema,Bettie Voordouw,Marion Koopmans,Annemiek A van der Eijk,Corien M Swaan,Margreet Jm Te Wierik,Tjalling Leenstra,Eline Op de Coul,Eelco Franz,Dutch Mpox Response Team,Members of the Dutch Mpox Response Team,Birgit van Benthem,Hanna Bos,Colette van Bokhoven-Rombouts,Lian Bovée,Chantal P Rovers,Brigitte van Cleef,Alje P van Dam,Rik van Dael,Jaap van Dissel,Pauline Ellerbroek,Catharina van Ewijk,Corine GeurtsvanKessel,Joke van der Giessen,Hannelore Götz,Josette Häger,Susan van den Hof,Elske Hoornenborg,Putri Hintaran,Jorgen de Jonge,Rosa Joosten,Kevin Kosterman,Jente Lange,André J Meeske,Liesbeth Mollema,Demi Reurings,Helma Ruijs,Linda Smid,Gregorius J Sips,Sacha F de Stoppelaar,Albert Vollaard,Karin Ellen Veldkamp,Klaartje Weijdema,Geert Westerhuis,Matthijs Welkers,Toos Waegemaekers,Paul Zantkuijl
DOI: https://doi.org/10.2807/1560-7917.ES.2023.28.12.2200772
Abstract:In early May 2022, a global outbreak of mpox started among persons without travel history to regions known to be enzootic for monkeypox virus (MPXV). On 8 August 2022, the Netherlands reported its 1,000th mpox case, representing a cumulative incidence of 55 per million population, one of the highest cumulative incidences worldwide. We describe characteristics of the first 1,000 mpox cases in the Netherlands, reported between 20 May and 8 August 2022, within the context of the public health response. These cases were predominantly men who have sex with men aged 31-45 years. The vast majority of infections were acquired through sexual contact with casual partners in private or recreational settings including LGBTQIA+ venues in the Netherlands. This indicates that, although some larger upsurges occurred from point-source and/or travel-related events, the outbreak was mainly characterised by sustained transmission within the Netherlands. In addition, we estimated the protective effect of first-generation smallpox vaccine against moderate/severe mpox and found a vaccine effectiveness of 58% (95% CI: 17-78%), suggesting moderate protection against moderate/severe mpox symptoms on top of any possible protection by this vaccine against MPXV infection and disease. Communication with and supporting the at-risk population in following mitigation measures remains essential.